SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
about
A Systematic Review of In vitro and In vivo Activities of Anti-Toxoplasma Drugs and Compounds (2006-2016).Improving the transport of chemotherapeutic drugs across the blood-brain barrier.Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB.Disseminated toxoplasmosis in non-allografted patients with hematologic malignancies: report of two cases and literature review.Nanocrystals for the parenteral delivery of poorly water-soluble drugsDrug nanosuspensions: a ZIP tool between traditional and innovative pharmaceutical formulations.Pyrimethamine-loaded lipid-core nanocapsules to improve drug efficacy for the treatment of toxoplasmosis.Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications.Formulation and characterization of atovaquone nanosuspension for improved oral delivery in the treatment of malaria.Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain.Neurological and Neuropsychiatric Consequences of Chronic Toxoplasma InfectionCelecoxib nanosuspension: single-step fabrication using a modified nanoprecipitation method and in vivo evaluationNanocrystals of Poorly Soluble Drugs: Drug Bioavailability and Physicochemical Stability
P2860
Q37594988-65A511E8-9C4B-4638-BAB3-B9FADD150AFFQ37960529-5C32C54D-4327-4EDF-B28D-4D53CFB02F21Q38075010-DE1E57D0-030E-491B-87CB-5CEC29E1018CQ38099782-950286A8-6DB3-49FD-ABCF-A750D7404D4DQ38104343-9D9D19CE-0649-4C1C-9EC1-17DFDF56316DQ38470559-42029FFB-831C-4C0E-A7FC-4EE9B2E8D048Q39051658-4545E819-77DF-439B-A1CF-DD0C2FE2F410Q39287046-504D2804-D547-4A83-938A-9747074F4227Q47833185-92C1C455-2E87-4732-BABC-00D7A338FAEAQ55413766-C223D2D3-DDD0-471E-BA58-B445CD209D53Q56156856-08A689A1-54DB-4581-BF3E-75CD85B46860Q58624617-701F5587-30AF-4A62-9D6C-872A3C9324E5Q58726467-0C15E36D-F64D-4553-B055-55DCC7B233BE
P2860
SDS-coated atovaquone nanosuspensions show improved therapeutic efficacy against experimental acquired and reactivated toxoplasmosis by improving passage of gastrointestinal and blood-brain barriers.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
SDS-coated atovaquone nanosusp ...... inal and blood-brain barriers.
@en
SDS-coated atovaquone nanosusp ...... inal and blood-brain barriers.
@nl
type
label
SDS-coated atovaquone nanosusp ...... inal and blood-brain barriers.
@en
SDS-coated atovaquone nanosusp ...... inal and blood-brain barriers.
@nl
prefLabel
SDS-coated atovaquone nanosusp ...... inal and blood-brain barriers.
@en
SDS-coated atovaquone nanosusp ...... inal and blood-brain barriers.
@nl
P2093
P2860
P1476
SDS-coated atovaquone nanosusp ...... inal and blood-brain barriers.
@en
P2093
Hend M Shubar
Klaus Borner
Markus M Heimesaat
Oliver Liesenfeld
Rachmat Mauludin
Rainer H Mueller
Rudolf Fitzner
Sabrina Lachenmaier
Uwe Lohman
P2860
P304
P356
10.3109/10611861003733995
P577
2010-04-01T00:00:00Z